Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4 results about "Heterografts" patented technology

Tissues, cells or organs transplanted between animals of different species.

Non-HLA matched humanized NSG mouse model with patient-derived xenograft

PendingUS20260185119A1HeterograftsNSG mouse
The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same.
Owner:JACKSON LAB THE

Methods and compositions for preventing herpes virus reactivation in organ xenograft

PCT designated stageWO2026064591A1Cell receptors/surface-antigens/surface-determinantsGenetically modified cellsHeterograftsHerpes simplex virus DNA
Disclosed herein include methods and compositions for pig-to-human organ xenotransplantation using genetically modified pigs with triple-gene knockouts and human gene insertions. In some embodiments, the organ xenotransplantation is a pig-to-human kidney xenotransplantation demonstrating the restoration of renal function. Also disclosed are methods and compositions for preventing acute rejection and / or reactivation of porcine herpesvirus, which contributes to advancing xenotransplantation as a viable solution to the global organ shortage.
Owner:ANTINOUS TECHNOLOGY CO LTD

Measuring the progress of cardiac xenograft immune rejection

PendingUS20260091096A1Peptide/protein ingredientsUnknown materialsAntigenHeterografts
This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine β1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and / or reduced or no endogenous α-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.
Owner:MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH